Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 is involved in cognitive brain function and learning, 98”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [98]
In the citing paper
“GLP1-RAs is known for its neuroprotective action, and more recent results have emerged, showing a potential benefit in people with AD [85,86,87].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [86]
In the citing paper
“They are involved in multiple biological pathways that could be beneficial in AD including improvement of BBB integrity and vascular health, promotion of homeostasis in microglia and astrocytes, positive effects on adaptative immune cells (including natural killer cells and activated regulatory T cells), improvement of synaptic viability, and neuroprotection [17–26].”
In the citing paper
“Preclinical results in murine models treated with GLP-1RAs suggest that the potential effects of semaglutide in AD may be exerted via impact on several AD-related pathophysiologic processes including neuroinflammatory pathways, vascular and BBB integrity, reduced synaptic loss, and neuroprotection [19, 21, 23–26, 46–48];”
Citations
Cites
Modification of seizure activity by electrical stimulation: II. Motor seizure
Racine, R. J. (1972) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(72)90177-0 · Cited by 7,171
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
The molecular biology of memory storage: a dialogue between genes and synapses
Kandel, E. R. (2001) · Science · doi:10.1126/science.1067020 · Cited by 3,917
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Indeed, GLP-1 exerts effects on glucose-dependent insulin secretion, insulin biosynthesis, gastrointestinal motility, islet b-cell neogenesis, energy homeostasis and food intak”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218 · cited 1×
“Immunohistochemical comparison of the CA3 subregion of the hippocampus using Fluorojade-B, a fluorochrome stain specific for degenerating neuron”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationEnvironmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective
Young, D., Lawlor, P. A., Leone, P., Dragunow, M., & During, M. J. (1999) · Nature Medicine · doi:10.1038/7449 · Cited by 732
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citation
Cited by
Items 301–400 of 859
Zhao, Y.-H., Li, H., Fang, F., Qin, T., Xiao, W., Wang, Z., & Ma, S. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.04.010 · Cited by 66
Liu, C., Carvalho, A., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130204031 · Cited by 61
Zhang, L.-Q., Zhang, W., Li, T., Yang, T., Yuan, X., Zhou, Y., Zou, Q., Yang, H., Gao, F., Tian, Y., et al. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107463 · Cited by 61
Llewellyn-Smith, I. J., Gnanamanickam, G. J. E., Reimann, F., Gribble, F. M., & Trapp, S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.071 · Cited by 61
Knippenberg, S., Thau, N., Dengler, R., Brinker, T., & Petri, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036857 · Cited by 61
Tamási, V., Petschner, P., Adori, C., Kirilly, E., Ando, R. D., Tothfalusi, L., Juhasz, G., & Bagdy, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113662 · Cited by 61
Panagaki, T., Michael, M., & Hölscher, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16488-x · Cited by 61
Lv, M., Xue, G., Cheng, H., Meng, P., Lian, X., Hölscher, C., & Li, D. (2021) · Brain and Behavior · doi:10.1002/brb3.2231 · Cited by 58
Ferrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 59
Kosaraju, J., Madhunapantula, S. V., Chinni, S., Khatwal, R. B., Dubala, A., Nataraj, S. K. M., & Basavan, D. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.03.026 · Cited by 67
Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes
Palleria, C., Leporini, C., Maida, F., Succurro, E., Sarro, G. D., Arturi, F., & Russo, E. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.07.002 · Cited by 66
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Ghosh, P., Fontanella, R. A., Scisciola, L., Pesapane, A., Taktaz, F., Franzese, M., Puocci, A., Ceriello, A., Prattichizzo, F., Rizzo, M. R., et al. (2023) · Theranostics · doi:10.7150/thno.86831 · Cited by 73
Ren, W., Chen, J., Wang, W., Li, Q., Yin, X., Zhuang, G., Zhou, H., & Zeng, W. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.012 · Cited by 68
Yang, D. W., Nakajo, Y., Iihara, K., Kataoka, H., & Yanamoto, H. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.015 · Cited by 64
GLP-1 and type 2 diabetes: physiology and new clinical advances
Combettes, M. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.003 · Cited by 69
Vessey, K. A., Rushforth, D. A., & Stell, W. K. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-1027 · Cited by 59
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
“Not much is known about the underlying mechanisms and efficacy of GLP-1 (9-36) in cerebral ischemia and reperfusion (CIR) injury (that is, middle cerebral artery was obstructed for some time and then achieved reperfusion).”
BackgroundInfluentialThe entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 72
Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease
Kim, J. Y., Barua, S., Jeong, Y. J., & Lee, J. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176419 · Cited by 65
Kim, S., Jeong, J., Jung, H.-S., Kim, B., Kim, Y.-E., Lim, D.-S., Kim, S.-D., & Song, Y. S. (2017) · Experimental Neurobiology · doi:10.5607/en.2017.26.4.227 · Cited by 57
Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy
von Jonquieres, G., Spencer, Z. H. T., Rowlands, B. D., Klugmann, C. B., Bongers, A., Harasta, A. E., Parley, K. E., Cederholm, J., Teahan, O., Pickford, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1784-9 · Cited by 57
Self-citationGLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Iwai, T., Suzuki, M., Kobayashi, K., Mori, K. J., Mogi, Y., & Oka, J. (2009) · Neuroscience Research · doi:10.1016/j.neures.2009.01.013 · Cited by 58
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Koshal, P., & Kumar, P. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2678-1 · Cited by 62
Brain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.
Chauhan, M., & Chauhan, N. B. (2015) · PubMed · Cited by 60
ten Kulve, J. S., Veltman, D. J., Gerdes, V. E. A., van Bloemendaal, L., Barkhof, F., Deacon, C. F., Holst, J. J., Drent, M. L., Diamant, M., & IJzerman, R. G. (2017) · Diabetes Care · doi:10.2337/dc16-2113 · Cited by 55
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54
Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., & Sun, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205207 · Cited by 54
Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota
Chung, J. Y., Jeong, J., & Song, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.588044 · Cited by 60
Carranza-Naval, M. J., del Marco, A., Hierro-Bujalance, C., Alves-Martinez, P., Infante-Garcia, C., Vargas-Soria, M., Herrera, M., Barba-Cordoba, B., Atienza-Navarro, I., Lubian-Lopez, S., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.741923 · Cited by 54
Hippocampus ghrelin receptor signaling promotes socially-mediated learned food preference
Hsu, T. M., Noble, E. E., Reiner, D. J., Liu, C. M., Suarez, A. N., Konanur, V. R., Hayes, M. R., & Kanoski, S. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.039 · Cited by 53
Perna, S., Mainardi, M., Astrone, P., Gozzer, C., Biava, A., Bacchio, R., Spadaccini, D., Solerte, S. B., & Rondanelli, M. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s164785 · Cited by 54
Potent and selective proline derived dipeptidyl peptidase IV inhibitors
Edmondson, S. D., Mastracchio, A., Beconi, M. G., Colwell, L. F., Habulihaz, B., He, H., Kumar, S., Leiting, B., Lyons, K. A., Mao, A., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.07.056 · Cited by 57
Fukuda, S., Nakagawa, S., Tatsumi, R., Morofuji, Y., Takeshita, T., Hayashi, K., Tanaka, K., Matsuo, T., & Niwa, M. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0696-1 · Cited by 53
Ishøy, P. L., Fagerlund, B., Broberg, B. V., Bak, N., Knop, F. K., Glenthoj, B. Y., & Ebdrup, B. H. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12711 · Cited by 59
Chen, T., Tian, P., Huang, Z., Zhao, X., Wang, H., Xia, C., Wang, L., & Wei, H. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9155-6 · Cited by 52
Chen, F., Wang, W., Ding, H., Yang, Q., Dong, Q., & Cui, M. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0661-0 · Cited by 52
Biswas, S. C., Buteau, J., & Greene, L. A. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9646-4 · Cited by 56
Suarez, A. N., Noble, E. E., & Kanoski, S. E. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00101 · Cited by 52
Yang, S., Wang, G., Feei, Z., Qin, L., Zhai, Y., Yu, Z., Xue, M., Zhang, Y., & Wan, Z. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201901019 · Cited by 52
Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans
Lerche, S., Brock, B., Rungby, J., Bøtker, H. E., Møller, N., Rodell, A., Bibby, B. M., Holst, J. J., Schmitz, O., & Gjedde, A. (2008) · Diabetes · doi:10.2337/db07-1162 · Cited by 52
Fu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 50
Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
Ceccarelli, E., Guarino, E. G., Merlotti, D., Patti, A., Gennari, L., Nuti, R., & Dotta, F. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00073 · Cited by 51
Role of Incretin Axis in Inflammatory Bowel Disease
Duan, L., Rao, X., Braunstein, Z., Toomey, A. C., & Zhong, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01734 · Cited by 57
Forny Germano, L., Koehler, J. A., Baggio, L. L., Cui, F., Wong, C. K., Rittig, N., Cao, X., Matthews, D., & Drucker, D. J. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102019 · Cited by 50
“:3) mice exhibited enhanced seizure severity and neuronal injury after kainate administration [10].”
Self-citationNeurobehavioral effects of liraglutide and sitagliptin in experimental models
Kamble, M., Gupta, R., Rehan, H. S., & Gupta, L. K. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.003 · Cited by 52
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Self-citationLi, X., Zhao, T., Gu, J., Wang, Z., Lin, J., Wang, R.-S., Duan, T., Li, Z., Dong, R., Wang, W., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00578-8 · Cited by 52
Foltynie, T., & Aviles-Olmos, I. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.005 · Cited by 49
Morris, L. C., Nance, K. D., Gentry, P. R., Days, E. L., Weaver, C. D., Niswender, C. M., Thompson, A. D., Jones, C. K., Locuson, C. W., Morrison, R. D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501375c · Cited by 47
Lin, T.-K., Lin, K.-J., Lin, H.-Y., Lin, K.-L., Lan, M.-Y., Wang, P.-W., Wang, T.-J., Wang, F.-S., Tsai, P.-C., Liou, C.-W., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697440 · Cited by 49
Insight into the role of DPP-4 in fibrotic wound healing
Zhang, K., Liu, S., Jia, Y., Zou, M., Teng, Y., Chen, Z.-H., Li, Y., Guo, D., Wu, J., Yuan, Z., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113143 · Cited by 52
Heile, A., & Brinker, T. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/aheile · Cited by 49
Bednářová, A., Kodrík, D., & Krishnan, N. (2012) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2012.10.012 · Cited by 55
Bader, M., Li, Y., Tweedie, D., Shlobin, N. A., Bernstein, A., Rubovitch, V., Tovar-y-Romo, L. B., DiMarchi, R. D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00356 · Cited by 48
Diabetes–Alzheimer's Disease Link: Targeting Mitochondrial Dysfunction and Redox Imbalance
Carvalho, C., & Cardoso, S. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8056 · Cited by 50
Edmondson, S. D., Mastracchio, A., Duffy, J. L., Eiermann, G. J., He, H., Ita, I. E., Leiting, B., Leone, J. F., Lyons, K. A., Makarewicz, A., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.028 · Cited by 48
Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice
Lennox, R., Flatt, P. R., & Gault, V. A. (2014) · Peptides · doi:10.1016/j.peptides.2014.08.014 · Cited by 47
Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Mansur, R. B., Lee, Y., Subramaniapillai, M., Brietzke, E., & McIntyre, R. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.048 · Cited by 47
Luciani, P., Deledda, C., Benvenuti, S., Cellai, I., Squecco, R., Monici, M., Cialdai, F., Luciani, G., Danza, G., Stefano, C. D., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0398-3 · Cited by 51
Rebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., & Fedele, E. (2018) · BioFactors · doi:10.1002/biof.1406 · Cited by 46
Pelle, M. C., Zaffina, I., Giofrè, F., Pujia, R., & Arturi, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411301 · Cited by 52
Špolcová, A., Mikulášková, B., Holubová, M., Nagelová, V., Pirnik, Z., Zemenová, J., Haluzík, M., Železná, B., Galas, M.-C., & Maletínská, L. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143150 · Cited by 46
Dixit, T. S., Sharma, A. N., Lucot, J. B., & Elased, K. M. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.03.008 · Cited by 46
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
Christensen, M., & Knop, F. K. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0102-x · Cited by 47
Kelly, P., McClean, P. L., Ackermann, M., Konerding, M. A., Hölscher, C., & Mitchell, C. A. (2015) · Microcirculation · doi:10.1111/micc.12186 · Cited by 46
Knezović, A., Barilar, J. O., Perhoč, A. B., Bagarić, R., Farkaš, V., Riederer, P. F., & Šalković‐Petrišić, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.027 · Cited by 49
Grigolon, R. B., Brietzke, E., Mansur, R. B., Idzikowski, M. A., Gerchman, F., De Felice, F. G., & McIntyre, R. S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109720 · Cited by 45
Ducharme, N. A., Banks, W. A., Morley, J. E., Robinson, S. M., Niehoff, M. L., Mattern, C., & Farr, S. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.05.033 · Cited by 49
Self-citationMcCarty, M. F., & DiNicolantonio, J. J. (2015) · Open Heart · doi:10.1136/openhrt-2014-000205 · Cited by 52
Effects of GLP-1 receptor agonists on neurological complications of diabetes
García-Casares, N., González-González, G., de la Cruz-Cosme, C., Garzón-Maldonado, F. J., de Rojas-Leal, C., Ariza, M. J., Narváez, M., Barbancho, M. Á., García-Arnés, J. A., & Tinahones, F. J. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09807-3 · Cited by 45
Dragonieri, S., Portacci, A., Quaranta, V. N., Carratù, P., Lázár, Z., Carpagnano, G. E., & Bikov, A. (2024) · Diseases · doi:10.3390/diseases12090224 · Cited by 51
Ohtake, N., Saito, M., Eto, M., & Seki, K. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.04.003 · Cited by 52
Moon, M. J., Park, S., Kim, D.-K., Cho, E. B., Hwang, J.-I., Vaudry, H., & Seong, J. Y. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00141 · Cited by 46
Roussel, B. D., Macrez, R., Jullienne, A., Agin, V., Maubert, E., Dauphinot, L., Potier, M., Plawinski, L., Castel, H., Hommet, Y., et al. (2009) · Brain · doi:10.1093/brain/awp162 · Cited by 50
Filho, A. J. M. C., Cunha, N. L., de Souza, A. G., Soares, M. V.-R., Jucá, P. M., de Queiroz, T., Oliveira, J. V. S., Valvassori, S. S., Barichello, T., Quevedo, J., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109872 · Cited by 50
Hölscher, C. (2014) · PubMed · Cited by 55
Gümüşlü, E., Mutlu, O., Celikyurt, I. K., Ulak, G., Akar, F., Erden, F., & Ertan, M. (2016) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12192 · Cited by 50
Babic, I., Gorak, A., Engel, M., Sellers, D., Else, P. L., Osborne, A. L., Pai, N. B., Huang, X., Nealon, J. R., & Weston–Green, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118756061 · Cited by 48
Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors
Edmondson, S. D., Mastracchio, A., Cox, J. M., Eiermann, G. J., He, H., Lyons, K. A., Patel, R. A., Patel, S. B., Petrov, A., Scapin, G., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.011 · Cited by 46
Vellai, T., McCulloch, D., Gems, D., & Kovács, A. L. (2006) · Genetics · doi:10.1534/genetics.106.061499 · Cited by 44
Yassine, H. N., Solomon, V., Thakral, A., Sheikh‐Bahaei, N., Chui, H. C., Braskie, M. N., Schneider, L. S., & Talbot, K. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12474 · Cited by 43
Cai, H.-Y., Wang, Z., Hölscher, C., Li, Y., Zhang, J., Sun, P., Li, J., Yang, W., Wu, M., & Qi, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.033 · Cited by 47
Impact of Early‐Life Weight Status on Cognitive Abilities in Children
Li, N., Yolton, K. A., Lanphear, B. P., Chen, A., Kalkwarf, H. J., & Braun, J. M. (2018) · Obesity · doi:10.1002/oby.22192 · Cited by 47
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Mahmoud, A. M. A., Mantawy, E. M., Wahdan, S. A., Ammar, R. M., & El‐Demerdash, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114238 · Cited by 45
Potentials of incretin‐based therapies in dementia and stroke in type 2 diabetes mellitus
Groeneveld, O. N., Kappelle, L. J., & Biessels, G. J. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12420 · Cited by 43
Koole, C., Savage, E. E., Christopoulos, A., Miller, L. J., Sexton, P. M., & Wootten, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1116 · Cited by 42
Brouillette, J., Young, D., During, M. J., & Quirion, R. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04666.x · Cited by 49
Self-citationMcGovern, S. F. J., Hunter, K., & Hölscher, C. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.029 · Cited by 47
Polyunsaturated fatty acids as putative cognitive enhancers
Yehuda, S. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.06.021 · Cited by 46
Manavi, M. A. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102250 · Cited by 40
Lemche, E., Killick, R., Mitchell, J., Caton, P., Choudhary, P., & Howard, J. K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106485 · Cited by 54
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 43
Sakr, H. F. (2013) · PubMed · Cited by 50
Brink, L., & Lönnerdal, B. L. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.05.004 · Cited by 48
Zhang, Y., Xie, J., Xu, X., Hu, J., Xu, T., Jin, S., Yang, S., & Wang, J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-018-00336-7 · Cited by 48
Metadata
- Authors
- During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., & Haile, C. N.
- Affiliations
- University of Auckland (NZ)
- Thomas Jefferson University (US)
- St. Louis VA Medical Center (US)
- University of Toronto (CA)
- Corresponding author
- During, Matthew J
- ORCID
- Venue
- Nature Medicine
- Published
- 2003-08-17
- Volume
- 9
- Issue
- 9
- Pages
- 1173-1179
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2124852816
- Cited by
- 851
- References
- 42
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 50 · 2023: 39 · 2022: 58 · 2021: 53 · 2020: 44 · 2019: 36 · 2018: 37 · 2017: 39 · 2016: 34 · 2015: 54 · 2014: 46 · 2013: 47 · 2012: 43
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Marsden Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, associative learning, spatial learning, memory, hippocampus, neuroprotection, kainate-induced seizures, neuronal apoptosis, cognitive enhancement, gut-brain signaling
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Administration, Intranasal, Amino Acid Sequence, Animals, Behavior, Animal, Cognition, Glucagon, Hippocampus, Kainic Acid, Learning, Male, Molecular Sequence Data, Neurons, Peptide Fragments, Protein Precursors, Seizures, Signal Transduction, Gene Expression, Rats, Sprague-Dawley, Apoptosis, Sequence Homology, Amino Acid, Gene Transfer Techniques, Receptors, Glucagon, Mice, Knockout, Neuroprotective Agents, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.